Please login to the form below

Omnichannel scientific engagement and the use of archetypes to drive personalization

Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.

One of the greatest commodities in the healthcare industry is the provision of medically relevant information to enable critical decision-making that ultimately optimizes patient outcomes. This is especially true when it comes to medical communications and scientific engagement. However, when working with complex stakeholder groups and large datasets in an increasingly saturated information and digital landscape, it can be hard to understand who your audience is and the best way to engage it.

During the past decade, biopharmaceutical scientific engagement within medical affairs has evolved across two key stages: from a brand-centric (Medical Affairs 1.0) approach to a focus on customer-centricity (Medical Affairs 2.0), which is where most of the biopharmaceutical industry is currently positioned. This shift has been enabled by the emergence of personalized medicine, digital technology, empowered patients—driven by greater access to information, richer datasets, and evidence sources.

However, there is an opportunity for medical affairs teams to move into a new third stage of engagement: a peri-/future-state stage we call “Medical Affairs 3.0.”

This new era is defined by the creation of medically informed networks, which facilitate expanded learning and connected peer-to-peer and personalized experiences for healthcare professionals. These networks are fueled by data, social proof, digital platforms, and rich insights into the customer.

At the recent 18th Annual Meeting of the International Society for Medical Publication Professionals (ISMPP), hosted in Washington, DC, Gary Lyons, Head of Strategy, discussed the role of personalized audience engagement in his plenary titled “Audience Segmentation: Omnichannel Scientific Engagement and the Use of Archetypes” built on the positioning of Medical Affairs 3.0.

Here, he explores the key themes and shares his recommendations for effectively engaging healthcare professionals at multiple touchpoints through an archetype-driven omnichannel strategy.

27th October 2022

Share

Tags

Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

Address:
No. 3 Booths Park
Booths Hall
Chelford Road
Knutsford
Cheshire
WA16 8GS
United Kingdom

Latest content on this profile

Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
Omnichannel scientific engagement and the use of archetypes to drive personalization
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.
Fishawack Health
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Fishawack Health